Thursday 16 October, 2025
Introduction/Objectives: To achieve long-term cure of the neglected tropical parasitic infection visceral leishmaniasis (VL), sufficient parasite eradication during treatment, as…
Read morePoster: Drug/Disease Modelling - Infection
Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients
Thursday 16 October, 2025
Objectives: There is a high need for new therapies for the neglected tropical parasitic disease visceral leishmaniasis (VL), as effective,…
Read moreParomomycin population pharmacokinetic analysis in Eastern African visceral leishmaniasis patients
Thursday 16 October, 2025
Objectives: In Eastern Africa, effective, safe and affordable combination treatments for visceral leishmaniasis (VL) are still lacking. Geographical variability in…
Read moreModeling of Interferon effector pathway after viral infection
Thursday 16 October, 2025
Objectives and backgroud: To develop a semi-mechanistic model describing the Interferon (IFN) type I signaling pathway after the administration of…
Read morePopulation Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria.
Thursday 16 October, 2025
Objectives: To analyse pooled data from four previously published trials on the pharmacokinetics of sulfadoxine and pyrimethamine in children and…
Read moreCorrelates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques
Thursday 16 October, 2025
Objectives: The long duration of therapy remains a challenge for the successful treatment of tuberculosis (TB). The study aimed to…
Read morePopulation pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients
Thursday 16 October, 2025
Objectives: Cycloserine or its structural analogue terizidone which consists of two molecules of cycloserine (1), is a key drug recommended…
Read moreTigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models
Thursday 16 October, 2025
Objectives: The enhanced activity of combination tigecycline (TIG) and tetracycline (TET) against Pseudomonas aeruginosa has been previously described in in vitro…
Read moreThe value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicin
Thursday 16 October, 2025
Objectives: This work evaluated a Bayesian model-based therapeutic drug monitoring (TDM) approach for rifampicin accounting for the known auto-induction and…
Read moreModelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy
Thursday 16 October, 2025
Objectives: The waist-hip ratio (WHR, unitless) is an anthropometric indicator of body fat distribution, calculated by dividing the circumference of the…
Read more